Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial: A randomized, controlled trial

Annals of Internal Medicine

Volumn 126, Issue 4, 1997, Pages 264-274

  Jabs, Douglas A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PROBENECID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETINITIS; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

EID: 1842294582     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-4-199702150-00002     Document Type: Article

References (37)

1. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 1996;124:633-42.
2. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med. 1993;329:1922-6.
3. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166:1223-7.
4. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989;107:75-80.
5. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-83.
6. Partel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5:1069-74.
7. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575-82.
8. Spector SA, Weingeist T, Pollard RB, Dieterich DT, Samo T, Benson CA, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1993;168: 557-63.
9. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992;326:213-20.
10. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology. 1994;101: 1250-61.
11. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS. 1995;9:471-7.
12. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995;333:615-20.
13. Palestine AG, Polis MA, De Smet MD, Baird BF, Falloon J, Kovacs JA, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115:665-73.
14. Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994;112:1531-9.
15. Bronson JJ, Ghazzouli I, Hitchcock MJ, Webb RR 2d, Martin JC. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine. J Med Chem. 1989;32:1457-63.
16. Hitchcock MJ, Woods K, Bronson J, Martin JC, Ho HT. Intracellular metabolism of the anti-herpes agent, (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine (HPMPC). Mol Pharmacol. 1992;41:197-202.
17. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988;32: 1839-44.
18. De Castro LM, Kern ER, De Clercq E, Ghaffar A, Mayer EP, Vogt PE, et al. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res. 1991;16:101-14.
19. Soike K, Huang JL, Zhang JY, Bohm R, Hitchcock MJ, Martin JC. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyllcytosine (HPMPC) on Simian Varicella infection in monkeys. Antiviral Res. 1991;16:17-28.
20. Li SB, Yang ZH, Feng JS, Fong CK, Lucia HL, Hsiung GD. Activity of (S)-1-[3-hydroxy-2-(phosphonylmethoxypropyl]cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 1990;13:237-52.
21. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995; 171:788-96.
22. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. Control Clin Trials. 1992;13:22-39.
23. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma. Cancer. 1948;1:634-56.
24. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
25. Petty BG, Kernhauser DM, Lietman PS. Zidovudine with probenecid: a warning [Letter]. Lancet. 1990;335:1044-5.
26. Ferris FL 3d, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91-6.
27. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch Ophthalmol. 1996;114:23-33.
28. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol. 1989;107:1759-66.
29. Altman DG. Practical Statistics for Medical Research. New York: Chapman & Hall; 1991.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-81.
31. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
32. Lin DO, Wei LS. The robust inference for the Cox proportional hazards model. Journal of the American Statistical Association. 1989;84:1074-7.
33. Breslow N. Test of hypotheses in an overdispersed Poisson regression and other quasi-likelihood models. Journal of the American Statistical Association. 1990;85:565-71.
34. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
35. Breslow N, Day NE. Statistical Methods in Cancer Research. Lyon, France: International Agency for Research on Cancer; 1989:93-4.
36. Kirsch LS, Arevalo JF, De Clercq E, Chavez de la Paz E, Munguia D, Garcia R, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1995;119:466-76.
37. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguia D, Azen SP, Freeman WR. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report. Ann Intern Med. 1996;125: 98-103.